https://www.selleckchem.com/pr....oducts/sar131675.htm
le to move toward human trials. Adjuvant surgical methods such as TAI show promise in humans but require more robust clinical evaluation. There is preliminary evidence that adjuvant treatments may mitigate the effects of ischemia/reperfusion injury. However, the pool of investigated pharmacological agents is wide, yet remarkably shallow; most compounds have been reported in a single animal study. To advance this field, a mechanism-based approach should be used to select promising agents that can be tested systematically. This will det
Respect!
Kommentar
Delen
